Half-Yearly Report on Genkyotex’s Liquidity Contract With Kepler Cheuvreux
06 Luglio 2021 - 6:02PM
Business Wire
Regulatory News:
Pursuant to the liquidity contract granted by Genkyotex
(Paris:GKTX) (Brussels:GKTX) to Kepler Cheuvreux, effective May 7,
2018, the following assets appeared on the liquidity account as of
June 30, 2021:
- 9,243 Genkyotex shares,
- 13,433.97 € in cash.
During the period of 01/01/2021 to 30/06/2021, no transactions
were carried out under the liquidity contract due to the
acquisition by Calliditas Therapeutics of a controlling interest in
Genkyotex in November 2020.
As a reminder, under the liquidity contract the following assets
appeared on the liquidity account at December 31, 2020:
- 9,243 Genkyotex shares,
- 13,467.52 € in cash.
During the period of 01/07/2020 to 31/12/2020, the following has
been executed: - 147 executions on buy side - 127 executions on
sell side
During the same period, the volume traded was as follows: -
18,814 shares for 47,956.14 euros on buy side - 21,036 shares for
54,129.05 euros on sell side
About Genkyotex Genkyotex is the leading
biopharmaceutical company in NOX therapies, listed on the Euronext
Paris and Euronext Brussels markets. Its leading platform enables
the identification of orally available small-molecules which
selectively inhibit specific NOX enzymes that amplify multiple
disease processes such as fibrosis, inflammation, pain processing,
cancer development, and neurodegeneration. Genkyotex is developing
a pipeline of first-in-class product candidates targeting one or
multiple NOX enzymes. The lead product candidate, setanaxib
(GKT831), a NOX1 and NOX4 inhibitor has shown evidence of
anti-fibrotic activity in a Phase II clinical trial in primary
biliary cholangitis (PBC). Clinical trials in PBC and head and neck
cancer with setanaxib are being planned in 2021 and investigator
led studies are supported by the Company in Type 1 Diabetes and
Kidney Disease (DKD) and in idiopathic pulmonary fibrosis (IPF), a
chronic lung disease that results in fibrosis of the lungs, are
ongoing. For further information, please go to
www.genkyotex.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210706005624/en/
GENKYOTEX Elias Papatheodorou CEO Tel.: +41 22 510 34 01
investors@genkyotex.com
NewCap Dušan Orešanský Tel.: +33 1 44 71 94 92
genkyotex@newcap.eu